Search

Your search keyword '"Paul, Friedemann"' showing total 2,961 results
Start Over Author "Paul, Friedemann"
2,961 results on '"Paul, Friedemann"'

104. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity

Author

Kedor, Claudia, Freitag, Helma, Meyer-Arndt, Lil, Wittke, Kirsten, Hanitsch, Leif G., Zoller, Thomas, Steinbeis, Fridolin, Haffke, Milan, Rudolf, Gordon, Heidecker, Bettina, Bobbert, Thomas, Spranger, Joachim, Volk, Hans-Dieter, Skurk, Carsten, Konietschke, Frank, Paul, Friedemann, Behrends, Uta, Bellmann-Strobl, Judith, and Scheibenbogen, Carmen

Published
2022
Full Text
View/download PDF

106. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial

Author

Cree, Bruce A C, primary, Kim, Ho Jin, additional, Weinshenker, Brian G, additional, Pittock, Sean J, additional, Wingerchuk, Dean M, additional, Fujihara, Kazuo, additional, Paul, Friedemann, additional, Cutter, Gary R, additional, Marignier, Romain, additional, Green, Ari J, additional, Aktas, Orhan, additional, Hartung, Hans-Peter, additional, She, Dewei, additional, Rees, William, additional, Smith, Michael, additional, Cimbora, Daniel, additional, Katz, Eliezer, additional, and Bennett, Jeffrey L, additional

Published
2024
Full Text
View/download PDF

107. Gait Variability as a Potential Motor Marker of Cerebellar Disease—Relationship between Variability of Stride, Arm Swing and Trunk Movements, and Walking Speed

Author

Kroneberg, Daniel, primary, Nümann, Astrid, additional, Minnerop, Martina, additional, Rönnefarth, Maria, additional, Endres, Matthias, additional, Kühn, Andrea A., additional, Paul, Friedemann, additional, Doss, Sarah, additional, Solbrig, Susanne, additional, Elshehabi, Morad, additional, Maetzler, Walter, additional, and Schmitz-Hübsch, Tanja, additional

Published
2024
Full Text
View/download PDF

109. Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S32.003)

Author

Pittock, Sean, primary, Barnett, Michael, additional, Bennett, Jeffrey, additional, Berthele, Achim, additional, De Seze, Jerome, additional, Levy, Michael, additional, Nakashima, Ichiro, additional, Oreja-Guevara, Celia, additional, Palace, Jacqueline, additional, Paul, Friedemann, additional, Pozzilli, Carlo, additional, Mashhoon, Yasmin, additional, Allen, Kerstin, additional, Parks, Becky, additional, and Kim, Ho Jin, additional

Published
2024
Full Text
View/download PDF

110. Long-term Comparative Efficacy of Inebilizumab in the AQP4+ Subpopulation from N-MOmentum Open-label Period Versus Azathioprine and Immunosuppressants and Versus Placebo in Patients with NMOSD (S32.001)

Author

Cree, Bruce, primary, Suero, Beatrice, additional, Walsh, Sarah, additional, Marignier, Romain, additional, Lindsey, John, additional, Kim, Ho Jin, additional, She, Dewei, additional, Cimbora, Daniel, additional, Patterson, Kristina, additional, and Paul, Friedemann, additional

Published
2024
Full Text
View/download PDF

113. N2 Year in Review

Author

Dalmau, Josep, Dalakas, Marinos C., Kolson, Dennis L., Paul, Friedemann, Sánchez-Valle, Raquel, and Zamvil, Scott S.

Published
2023
Full Text
View/download PDF

114. Myelin-oligodendrocyte glycoprotein antibody-associated disease

Author

Marignier, Romain, Hacohen, Yael, Cobo-Calvo, Alvaro, Pröbstel, Anne-Katrin, Aktas, Orhan, Alexopoulos, Harry, Amato, Maria-Pia, Asgari, Nasrin, Banwell, Brenda, Bennett, Jeffrey, Brilot, Fabienne, Capobianco, Marco, Chitnis, Tanuja, Ciccarelli, Olga, Deiva, Kumaran, De Sèze, Jérôme, Fujihara, Kazuo, Jacob, Anu, Kim, Ho Jin, Kleiter, Ingo, Lassmann, Hans, Leite, Maria-Isabel, Linington, Christopher, Meinl, Edgar, Palace, Jacqueline, Paul, Friedemann, Petzold, Axel, Pittock, Sean, Reindl, Markus, Sato, Douglas Kazutoshi, Selmaj, Krzysztof, Siva, Aksel, Stankoff, Bruno, Tintore, Mar, Traboulsee, Anthony, Waters, Patrick, Waubant, Emmanuelle, Weinshenker, Brian, Derfuss, Tobias, Vukusic, Sandra, and Hemmer, Bernhard

Published
2021
Full Text
View/download PDF

115. Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort

Author

Kenney, Rachel, Liu, Mengling, Hasanaj, Lisena, Joseph, Binu, Al-Hassan, Abdullah A., Balk, Lisanne, Behbehani, Raed, Brandt, Alexander U., Calabresi, Peter A., Frohman, Elliot M., Frohman, Teresa, Havla, Joachim, Hemmer, Bernhard, Jiang, Hong, Knier, Benjamin, Korn, Thomas, Leocani, Letizia, Martínez-Lapiscina, Elena H., Papadopoulou, Athina, Paul, Friedemann, Petzold, Axel, Pisa, Marco, Villoslada, Pablo, Zimmermann, Hanna, Ishikawa, Hiroshi, Schuman, Joel S., Wollstein, Gadi, Chen, Yu, Saidha, Shiv, Thorpe, Lorna E., Galetta, Steven L., and Balcer, Laura J.

Published
2022
Full Text
View/download PDF

116. High risk of postpartum relapses in neuromyelitis optica spectrum disorder

Author

Klawiter, Eric C, Bove, Riley, Elsone, Liene, Alvarez, Enrique, Borisow, Nadja, Cortez, Melissa, Mateen, Farrah, Mealy, Maureen A, Sorum, Jaime, Mutch, Kerry, Tobyne, Sean M, Ruprecht, Klemens, Buckle, Guy, Levy, Michael, Wingerchuk, Dean, Paul, Friedemann, Cross, Anne H, Jacobs, Anu, Chitnis, Tanuja, and Weinshenker, Brian

Subjects
Clinical Research, Reproductive health and childbirth, Adolescent, Adult, Aged, Aged, 80 and over, Disability Evaluation, Electronic Health Records, Female, Humans, Immunologic Factors, Middle Aged, Neuromyelitis Optica, Postpartum Period, Pregnancy, Pregnancy Complications, Recurrence, Risk, Young Adult, Clinical Sciences, Neurosciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

OBJECTIVE:To study the effect of pregnancy on the frequency of neuromyelitis optica spectrum disorder (NMOSD) relapse and evaluate rates of pregnancy-related complications in an international multicenter setting. METHODS:We administered a standardized survey to 217 women with NMOSD from 7 medical centers and reviewed their medical records. We compared the annualized relapse rate (ARR) during a baseline period 2 years prior to a participant's first pregnancy to that during pregnancy and to the 9 months postpartum. We also assessed pregnancy-related complications. RESULTS:There were 46 informative pregnancies following symptom onset in 31 women with NMOSD. Compared to baseline (0.17), ARR was increased both during pregnancy (0.44; p = 0.035) and during the postpartum period (0.69; p = 0.009). The highest ARR occurred during the first 3 months postpartum (ARR 1.33). A total of 8 of 76 (10.5%) with onset of NMOSD prior to age 40 experienced their initial symptom during the 3 months postpartum, 2.9 times higher than expected. CONCLUSIONS:The postpartum period is a particularly high-risk time for initial presentation of NMOSD. In contrast to published observations in multiple sclerosis, in neuromyelitis optica, relapse rate during pregnancy was also increased, although to a lesser extent than after delivery.

Published
2017

117. Caution, “normal” BMI: health risks associated with potentially masked individual underweight—EPMA Position Paper 2021

Author

Golubnitschaja, Olga, Liskova, Alena, Koklesova, Lenka, Samec, Marek, Biringer, Kamil, Büsselberg, Dietrich, Podbielska, Halina, Kunin, Anatolij A., Evsevyeva, Maria E., Shapira, Niva, Paul, Friedemann, Erb, Carl, Dietrich, Detlef E., Felbel, Dieter, Karabatsiakis, Alexander, Bubnov, Rostyslav, Polivka, Jiri, Polivka, Jr, Jiri, Birkenbihl, Colin, Fröhlich, Holger, Hofmann-Apitius, Martin, and Kubatka, Peter

Published
2021
Full Text
View/download PDF

119. Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis

Author

Hoffmann,Olaf, Paul,Friedemann, Haase,Rocco, Kern,Raimar, Ziemssen,Tjalf, Hoffmann,Olaf, Paul,Friedemann, Haase,Rocco, Kern,Raimar, and Ziemssen,Tjalf

Abstract

Olaf Hoffmann,1– 3 Friedemann Paul,3,4 Rocco Haase,5 Raimar Kern,6 Tjalf Ziemssen51Department of Neurology, Alexianer St. Josefs-Krankenhaus Potsdam, Potsdam, Germany; 2Medizinische Hochschule Brandenburg Theodor Fontane, Neuruppin, Germany; 3Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany; 4Max Delbrueck Center for Molecular Medicine, Berlin, Germany; 5Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; 6MedicalSyn GmbH, Stuttgart, GermanyCorrespondence: Olaf Hoffmann, Alexianer St. Josefs-Krankenhaus Potsdam, Department of Neurology, Allee nach Sanssouci 7, 14471 Potsdam, Brandenburg, Germany, Tel +49 331 9682 6000, Fax +49 331 9682 6009, Email o.hoffmann@alexianer.deBackground: To reduce the risk of long-term disability in people with Multiple Sclerosis (pwMS), an increasing number of disease-modifying immune therapies (DMT) are available, involving diverse mechanisms of action, levels of efficacy, treatment risks, and tolerability aspects. Including patient preferences and expectations in shared decision-making may improve treatment satisfaction, adherence, and persistence.Purpose: To investigate long-term alignment of individual preferences and expectations of pwMS with their actual DMT and its effect on treatment satisfaction, health-related quality of life (HRQoL), adherence, and treatment discontinuation.Methods: A total of 401 pwMS beginning a new DMT were enrolled from 2015 to 2018 in a non-interventional study at three German MS centres. Patient preferences regarding DMT, TSQM-9, SF36, and self-reported adherence as well as relapses and EDSS were recorded at baseline and every 3 to 6 months for up to 3 years.Results: Efficacy and tolerability were the highest-ranking preferences at baselin

Published
2024

125. A future of AI-driven personalized care for people with multiple sclerosis.

Author

Praet, Jelle, Anderhalten, Lina, Comi, Giancarlo, Horakova, Dana, Ziemssen, Tjalf, Vermersch, Patrick, Lukas, Carsten, van Leemput, Koen, Steppe, Marjan, Aguilera, Cristina, Kadas, Ella Maria, Bertrand, Alexis, van Rampelbergh, Jean, de Boer, Erik, Zingler, Vera, Smeets, Dirk, Ribbens, Annemie, and Paul, Friedemann

Subjects
DIAGNOSIS, QUALITY of life, PROGNOSTIC models, CENTRAL nervous system, MULTIPLE sclerosis
Abstract

Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system resulting in progressive disability accumulation. As there is no cure available yet for MS, the primary therapeutic objective is to reduce relapses and to slow down disability progression as early as possible during the disease to maintain and/or improve health-related quality of life. However, optimizing treatment for people with MS (pwMS) is complex and challenging due to the many factors involved and in particular, the high degree of clinical and subclinical heterogeneity in disease progression among pwMS. In this paper, we discuss these many different challenges complicating treatment optimization for pwMS as well as how a shift towards a more pro-active, data-driven and personalized medicine approach could potentially improve patient outcomes for pwMS. We describe how the ‘Clinical Impact through AI-assisted MS Care’ (CLAIMS) project serves as a recent example of how to realize such a shift towards personalized treatment optimization for pwMS through the development of a platform that offers a holistic view of all relevant patient data and biomarkers, and then using this data to enable AI-supported prognostic modelling. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

126. Altered brain perfusion and oxygen levels relate to sleepiness and attention in post‐COVID syndrome.

Author

Chien, Claudia, Heine, Josephine, Khalil, Ahmed, Schlenker, Lars, Hartung, Tim J., Boesl, Fabian, Schwichtenberg, Katia, Rust, Rebekka, Bellmann‐Strobl, Judith, Franke, Christiana, Paul, Friedemann, and Finke, Carsten

Subjects
FUNCTIONAL magnetic resonance imaging, FATIGUE (Physiology), FALSE discovery rate, CAUDATE nucleus, ISOLATION perfusion
Abstract

Objective: Persisting neurological symptoms after COVID‐19 affect up to 10% of patients and can manifest in fatigue and cognitive complaints. Based on recent evidence, we evaluated whether cerebral hemodynamic changes contribute to post‐COVID syndrome (PCS). Methods: Using resting‐state functional magnetic resonance imaging, we investigated brain perfusion and oxygen level estimates in 47 patients (44.4 ± 11.6 years; F:M = 38:9) and 47 individually matched healthy control participants. Group differences were calculated using two‐sample t‐tests. Multivariable linear regression was used for associations of each regional perfusion and oxygen level measure with cognition and sleepiness measures. Exploratory hazard ratios were calculated for each brain metric with clinical measures. Results: Patients presented with high levels of fatigue (79%) and daytime sleepiness (45%). We found widespread decreased brain oxygen levels, most evident in the white matter (false discovery rate adjusted‐p‐value (p‐FDR) = 0.038) and cortical grey matter (p‐FDR = 0.015). Brain perfusion did not differ between patients and healthy participants. However, delayed patient caudate nucleus perfusion was associated with better executive function (p‐FDR = 0.008). Delayed perfusion in the cortical grey matter and hippocampus were associated with a reduced risk of daytime sleepiness (hazard ratio (HR) = 0.07, p = 0.037 and HR = 0.06, p = 0.034). Decreased putamen oxygen levels were associated with a reduced risk of poor cognitive outcome (HR = 0.22, p = 0.019). Meanwhile, lower thalamic oxygen levels were associated with a higher risk of cognitive fatigue (HR = 6.29, p = 0.017). Interpretation: Our findings of lower regional brain blood oxygen levels suggest increased cerebral metabolism in PCS, which potentially holds a compensatory function. These hemodynamic changes were related to symptom severity, possibly representing metabolic adaptations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

127. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody‐associated Disease, Aquaporin‐4 Antibody‐Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis

Author

Cortese, Rosa, Battaglini, Marco, Prados, Ferran, Gentile, Giordano, Luchetti, Ludovico, Bianchi, Alessia, Haider, Lukas, Jacob, Anu, Palace, Jacqueline, Messina, Silvia, Paul, Friedemann, Marignier, Romain, Durand‐Dubief, Françoise, de Medeiros Rimkus, Carolina, Apostolos Pereira, Samira Luisa, Sato, Douglas Kazutoshi, Filippi, Massimo, Rocca, Maria Assunta, Cacciaguerra, Laura, and Rovira, Àlex

Subjects
NEUROMYELITIS optica, MYELIN oligodendrocyte glycoprotein, WHITE matter (Nerve tissue), AQUAPORINS, ATROPHY, MULTIPLE sclerosis
Abstract

Objective: To evaluate: (1) the distribution of gray matter (GM) atrophy in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), aquaporin‐4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4+NMOSD), and relapsing–remitting multiple sclerosis (RRMS); and (2) the relationship between GM volumes and white matter lesions in various brain regions within each disease. Methods: A retrospective, multicenter analysis of magnetic resonance imaging data included patients with MOGAD/AQP4+NMOSD/RRMS in non‐acute disease stage. Voxel‐wise analyses and general linear models were used to evaluate the relevance of regional GM atrophy. For significant results (p < 0.05), volumes of atrophic areas are reported. Results: We studied 135 MOGAD patients, 135 AQP4+NMOSD, 175 RRMS, and 144 healthy controls (HC). Compared with HC, MOGAD showed lower GM volumes in the temporal lobes, deep GM, insula, and cingulate cortex (75.79 cm3); AQP4+NMOSD in the occipital cortex (32.83 cm3); and RRMS diffusely in the GM (260.61 cm3). MOGAD showed more pronounced temporal cortex atrophy than RRMS (6.71 cm3), whereas AQP4+NMOSD displayed greater occipital cortex atrophy than RRMS (19.82 cm3). RRMS demonstrated more pronounced deep GM atrophy in comparison with MOGAD (27.90 cm3) and AQP4+NMOSD (47.04 cm3). In MOGAD, higher periventricular and cortical/juxtacortical lesions were linked to reduced temporal cortex, deep GM, and insula volumes. In RRMS, the diffuse GM atrophy was associated with lesions in all locations. AQP4+NMOSD showed no lesion/GM volume correlation. Interpretation: GM atrophy is more widespread in RRMS compared with the other two conditions. MOGAD primarily affects the temporal cortex, whereas AQP4+NMOSD mainly involves the occipital cortex. In MOGAD and RRMS, lesion‐related tract degeneration is associated with atrophy, but this link is absent in AQP4+NMOSD. ANN NEUROL 2024;96:276–288 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

132. An exploratory research report on brain mineralization in postoperative delirium and cognitive decline

Author

Lammers‐Lietz, Florian, primary, Borchers, Friedrich, additional, Feinkohl, Insa, additional, Hetzer, Stefan, additional, Kanar, Cicek, additional, Konietschke, Frank, additional, Lachmann, Gunnar, additional, Chien, Claudia, additional, Spies, Claudia, additional, Winterer, Georg, additional, Zaborszky, Laszlo, additional, Zacharias, Norman, additional, and Paul, Friedemann, additional

Published
2024
Full Text
View/download PDF

133. Multiscale networks in multiple sclerosis

Author

Kennedy, Keith E., primary, Kerlero de Rosbo, Nicole, additional, Uccelli, Antonio, additional, Cellerino, Maria, additional, Ivaldi, Federico, additional, Contini, Paola, additional, De Palma, Raffaele, additional, Harbo, Hanne F., additional, Berge, Tone, additional, Bos, Steffan D., additional, Høgestøl, Einar A., additional, Brune-Ingebretsen, Synne, additional, de Rodez Benavent, Sigrid A., additional, Paul, Friedemann, additional, Brandt, Alexander U., additional, Bäcker-Koduah, Priscilla, additional, Behrens, Janina, additional, Kuchling, Joseph, additional, Asseyer, Susanna, additional, Scheel, Michael, additional, Chien, Claudia, additional, Zimmermann, Hanna, additional, Motamedi, Seyedamirhosein, additional, Kauer-Bonin, Josef, additional, Saez-Rodriguez, Julio, additional, Rinas, Melanie, additional, Alexopoulos, Leonidas G., additional, Andorra, Magi, additional, Llufriu, Sara, additional, Saiz, Albert, additional, Blanco, Yolanda, additional, Martinez-Heras, Eloy, additional, Solana, Elisabeth, additional, Pulido-Valdeolivas, Irene, additional, Martinez-Lapiscina, Elena H., additional, Garcia-Ojalvo, Jordi, additional, and Villoslada, Pablo, additional

Published
2024
Full Text
View/download PDF

136. Differentiation between Parkinson’s Disease and the Parkinsonian Subtype of Multiple System Atrophy Using the Magnetic Resonance T1w/T2w Ratio in the Middle Cerebellar Peduncle

Author

Wang, Jiaqi, primary, Sugiyama, Atsuhiko, additional, Yokota, Hajime, additional, Hirano, Shigeki, additional, Yamamoto, Tatsuya, additional, Yamanaka, Yoshitaka, additional, Araki, Nobuyuki, additional, Ito, Shoichi, additional, Paul, Friedemann, additional, and Kuwabara, Satoshi, additional

Published
2024
Full Text
View/download PDF

137. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry

Author

Frahm, Niklas, primary, Ellenberger, David, additional, Stahmann, Alexander, additional, Fneish, Firas, additional, Lüftenegger, Daniel, additional, Salmen, Hans C., additional, Schirduan, Ksenija, additional, Schaak, Tom P. A., additional, Flachenecker, Peter, additional, Kleinschnitz, Christoph, additional, Paul, Friedemann, additional, Krefting, Dagmar, additional, Zettl, Uwe K., additional, Peters, Melanie, additional, and Warnke, Clemens, additional

Published
2024
Full Text
View/download PDF

140. Restoring immune tolerance in neuromyelitis optica

Author

Steinman, Larry, Bar-Or, Amit, Behne, Jacinta M, Benitez-Ribas, Daniel, Chin, Peter S, Clare-Salzler, Michael, Healey, Donald, Kim, James I, Kranz, David M, Lutterotti, Andreas, Martin, Roland, Schippling, Sven, Villoslada, Pablo, Wei, Cheng-Hong, Weiner, Howard L, Zamvil, Scott S, Yeaman, Michael R, Smith, Terry J, Aktas, Orhan, Amezcua, Lilyana, Appiwatanakul, Metha, Asgari, Nasrin, Banwell, Brenda, Bennett, Jeffrey, Bowen, James, Cabre, Philippe, Chitnis, Tanuja, Cohen, Jeffrey, De Seze, Jerome, Fujihara, Kazuo, Han, May, Hellwig, Kerstin, Hintzen, Rogier, Hooper, D Craig, Iorio, Raffaele, Jacob, Anu, Jarius, Sven, Kim, Ho Jin, Kissani, Najib, Klawiter, Eric C, Kleiter, Ingo, Lana-Peixoto, Marco, Leite, Maria Isabel, Levy, Michael, Lublin, Fred, Draayer, Yang Mao, Marignier, Romain, Matiello, Marcelo, Nakashima, Ichiro, O’Connor, Kevin C, Palace, Jacqueline, Pandit, Lekha, Paul, Friedemann, Prayoonwiwat, Naraporn, Riley, Claire, Ruprecht, Klemens, Saiz, Albert, Siritho, Sasitorn, Tenembaum, Silvia, Weinshenker, Brian, Wingerchuk, Dean, and Würfel, Jens

Subjects
Biomedical and Clinical Sciences, Immunology, Neurosciences, Neurodegenerative, Eye Disease and Disorders of Vision, Multiple Sclerosis, Clinical Research, Brain Disorders, Autoimmune Disease, Aetiology, 2.1 Biological and endogenous factors
Abstract

Neuromyelitis optica (NMO) and spectrum disorder (NMO/SD) represent a vexing process and its clinical variants appear to have at their pathogenic core the loss of immune tolerance to the aquaporin-4 water channel protein. This process results in a characteristic pattern of astrocyte dysfunction, loss, and demyelination that predominantly affects the spinal cord and optic nerves. Although several empirical therapies are currently used in the treatment of NMO/SD, none has been proven effective in prospective, adequately powered, randomized trials. Furthermore, most of the current therapies subject patients to long-term immunologic suppression that can cause serious infections and development of cancers. The following is the first of a 2-part description of several key immune mechanisms in NMO/SD that might be amenable to therapeutic restoration of immune tolerance. It is intended to provide a roadmap for how potential immune tolerance restorative techniques might be applied to patients with NMO/SD. This initial installment provides a background rationale underlying attempts at immune tolerization. It provides specific examples of innovative approaches that have emerged recently as a consequence of technical advances. In several autoimmune diseases, these strategies have been reduced to practice. Therefore, in theory, the identification of aquaporin-4 as the dominant autoantigen makes NMO/SD an ideal candidate for the development of tolerizing therapies or cures for this increasingly recognized disease.

Published
2016

141. Restoring immune tolerance in neuromyelitis optica

Author

Bar-Or, Amit, Steinman, Larry, Behne, Jacinta M, Benitez-Ribas, Daniel, Chin, Peter S, Clare-Salzler, Michael, Healey, Donald, Kim, James I, Kranz, David M, Lutterotti, Andreas, Martin, Roland, Schippling, Sven, Villoslada, Pablo, Wei, Cheng-Hong, Weiner, Howard L, Zamvil, Scott S, Smith, Terry J, Yeaman, Michael R, Aktas, Orhan, Amezcua, Lilyana, Appiwatanakul, Metha, Asgari, Nasrin, Banwell, Brenda, Bennett, Jeffrey, Bowen, James, Cabre, Philippe, Chitnis, Tanuja, Cohen, Jeffrey, De Seze, Jerome, Fujihara, Kazuo, Han, May, Hellwig, Kerstin, Hintzen, Rogier, Hooper, D Craig, Iorio, Raffaele, Jacob, Anu, Jarius, Sven, Kim, Ho Jin, Kissani, Najib, Klawiter, Eric C, Kleiter, Ingo, Lana-Peixoto, Marco, Leite, Maria Isabel, Levy, Michael, Lublin, Fred, Draayer, Yang Mao, Marignier, Romain, Matiello, Marcelo, Nakashima, Ichiro, O’Connor, Kevin C, Palace, Jacqueline, Pandit, Lekha, Paul, Friedemann, Prayoonwiwat, Naraporn, Riley, Claire, Ruprecht, Klemens, Saiz, Albert, Siritho, Sasitorn, Tenembaum, Silvia, Weinshenker, Brian, Wingerchuk, Dean, and Würfel, Jens

Subjects
Biomedical and Clinical Sciences, Immunology, Multiple Sclerosis, Autoimmune Disease, Neurosciences, Brain Disorders, Neurodegenerative, Eye Disease and Disorders of Vision, Aetiology, 2.1 Biological and endogenous factors
Abstract

Neuromyelitis optica spectrum disorder (NMO/SD) and its clinical variants have at their core the loss of immune tolerance to aquaporin-4 and perhaps other autoantigens. The characteristic phenotype is disruption of astrocyte function and demyelination of spinal cord, optic nerves, and particular brain regions. In this second of a 2-part article, we present further perspectives regarding the pathogenesis of NMO/SD and how this disease might be amenable to emerging technologies aimed at restoring immune tolerance to disease-implicated self-antigens. NMO/SD appears to be particularly well-suited for these strategies since aquaporin-4 has already been identified as the dominant autoantigen. The recent technical advances in reintroducing immune tolerance in experimental models of disease as well as in humans should encourage quantum leaps in this area that may prove productive for novel therapy. In this part of the article series, the potential for regulatory T and B cells is brought into focus, as are new approaches to oral tolerization. Finally, a roadmap is provided to help identify potential issues in clinical development and guide applications in tolerization therapy to solving NMO/SD through the use of emerging technologies. Each of these perspectives is intended to shine new light on potential cures for NMO/SD and other autoimmune diseases, while sparing normal host defense mechanisms.

Published
2016

142. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies

Author

Cruz-Herranz, Andrés, Balk, Lisanne J, Oberwahrenbrock, Timm, Saidha, Shiv, Martinez-Lapiscina, Elena H, Lagreze, Wolf A, Schuman, Joel S, Villoslada, Pablo, Calabresi, Peter, Balcer, Laura, Petzold, Axel, Green, Ari J, Paul, Friedemann, Brandt, Alexander U, Albrecht, Philipp, Imitola, Jaime, Toosy, Ahmed, Zimmermann, Hanna, Outteryck, Olivier, Nolan, Rachel, Kolbe, Scott, Battistini, Jette Lautrup Frederiksen, Aktas, Orhan, Leocani, Letizia, Yeh, Ann, Havla, Joachim, Ringelstein, Marius, Pihl-Jensen, Gorm, Preiningerova, Jana L, Schippling, Sven, and Costello, Fiona

Subjects
Bioengineering, Biomedical Imaging, Neurosciences, Clinical Research, Generic health relevance, Checklist, Humans, Research Design, Terminology as Topic, Tomography, Optical Coherence, IMSVISUAL consortium, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo develop consensus recommendations for reporting of quantitative optical coherence tomography (OCT) study results.MethodsA panel of experienced OCT researchers (including 11 neurologists, 2 ophthalmologists, and 2 neuroscientists) discussed requirements for performing and reporting quantitative analyses of retinal morphology and developed a list of initial recommendations based on experience and previous studies. The list of recommendations was subsequently revised during several meetings of the coordinating group.ResultsWe provide a 9-point checklist encompassing aspects deemed relevant when reporting quantitative OCT studies. The areas covered are study protocol, acquisition device, acquisition settings, scanning protocol, funduscopic imaging, postacquisition data selection, postacquisition data analysis, recommended nomenclature, and statistical analysis.ConclusionsThe Advised Protocol for OCT Study Terminology and Elements recommendations include core items to standardize and improve quality of reporting in quantitative OCT studies. The recommendations will make reporting of quantitative OCT studies more consistent and in line with existing standards for reporting research in other biomedical areas. The recommendations originated from expert consensus and thus represent Class IV evidence. They will need to be regularly adjusted according to new insights and practices.

Published
2016

143. MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis

Author

Kotelnikova, Ekaterina, Kiani, Narsis A., Messinis, Dimitris, Pertsovskaya, Inna, Pliaka, Vicky, Bernardo-Faura, Marti, Rinas, Melanie, Vila, Gemma, Zubizarreta, Irati, Pulido-Valdeolivas, Irene, Sakellaropoulos, Theodore, Faigle, Wolfgang, Silberberg, Gilad, Masso, Mar, Stridh, Pernilla, Behrens, Janina, Olsson, Tomas, Martin, Roland, Paul, Friedemann, Alexopoulos, Leonidas G., Saez-Rodriguez, Julio, Tegner, Jesper, and Villoslada, Pablo

Published
2019

144. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial

Author

Vermersch, Patrick, Brieva-Ruiz, Luis, Fox, Robert J., Paul, Friedemann, Ramio-Torrenta, Lluis, Schwab, Matthias, Moussy, Alain, Mansfield, Colin, Hermine, Olivier, Maciejowski, Maciej, Hecham, N., Deri, N. Haydeé, Djelilovic-Vranic, J., Milanov, I., Shotekov, P., Blevins, G., Girard, J., Lapierre, Y., Camu, W., Castelnovo, G., Clavelou, P., Hautecoeur, P., Marziniak, M., Mayer, C., Oschmann, P., Reifschneider, G., Schoell, I., Tackenberg, B., Bergh, F. Then, Fakas, N., Grigoriadis, N., Kalochristianakis, D., Mitsikostas, D., Orologas, A., Tavernarakis, A., Thomaidis, T., Kovacs, K., Matyas, K., Piros, P., Satori, M., Anand, K., Shifrin, A., Banaszkiewicz, K., Bonek, R., Chahwan, M., Czernichowska - Kotiuszko, M., Darda-Ledzion, L., Debrowska - Wójcik, J., Dziki, M., Krzystanek, E., Kulka, M., Lisewski, P., Ratajczak, M., Szczudlik, A., Szczygiel, J., Tomaszewska, M., Wójcik, J., Zielonka, D., Chiru, M., Deme, S., Manescu, S., Nica, SM., Popescu, C., Szatmari, S., Fedyanin, A., Malkova, N., Popov, D., Volkova, L., Vorobeva, O., Brozman, M., Cimprichova, A., Cuchran, P., Gurcik, L., Krastev, G., Lisá, I., Nyeky, M., Poljaková, J., Turcani, P., Frost, A., Heckmann, J., Agüera, E., Coret, F., Escartin, A., Fernandez, V., Callizo, JR. Ara, Martin, G., Martinez-Rodriguez, JE., Gines, M. Martinez, Munoz, D., Olascoaga, J., Prieto, J., Ramo-Tello, C., Belal, S., Ben Ammou, S., Frih-Ayed, M., Gouider, R., Mhiri, C., Mrissa, R., Cherkez, A., Chmyr, H., Chudovska, L., Datskevych, S., Dziak, L., Galusha, A., Khavunka, M., Kobys, T., Kozyolkin, O., Lekomtseva, Y., Litovchenko, T., Moroz, O., Moskovko, G., Pashkovsky, V., Sanotskyi, Y., Shkrobot, S., Braley, T., Conway, J., Hughes, B., Katz, A., Rizvi, S., and Singer, R.

Published
2022
Full Text
View/download PDF

145. Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis

Author

Müller, Jannis, Sinnecker, Tim, Wendebourg, Maria Janina, Schläger, Regina, Kuhle, Jens, Schädelin, Sabine, Benkert, Pascal, Derfuss, Tobias, Cattin, Philippe, Jud, Christoph, Spiess, Florian, Amann, Michael, Lincke, Therese, Barakovic, Muhamed, Cagol, Alessandro, Tsagkas, Charidimos, Parmar, Katrin, Pröbstel, Anne-Katrin, Reimann, Sophia, Asseyer, Susanna, Duchow, Ankelien, Brandt, Alexander, Ruprecht, Klemens, Hadjikhani, Nouchine, Fukumoto, Shoko, Watanabe, Mitsuru, Masaki, Katsuhisa, Matsushita, Takuya, Isobe, Noriko, Kira, Jun-Ichi, Kappos, Ludwig, Würfel, Jens, Granziera, Cristina, Paul, Friedemann, and Yaldizli, Özgür

Published
2022
Full Text
View/download PDF

149. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Author

Kremer, Stephane, Renard, Felix, Achard, Sophie, Lana-Peixoto, Marco A, Palace, Jacqueline, Asgari, Nasrin, Klawiter, Eric C, Tenembaum, Silvia N, Banwell, Brenda, Greenberg, Benjamin M, Bennett, Jeffrey L, Levy, Michael, Villoslada, Pablo, Saiz, Albert, Fujihara, Kazuo, Chan, Koon Ho, Schippling, Sven, Paul, Friedemann, Kim, Ho Jin, de Seze, Jerome, Wuerfel, Jens T, Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre, Philippe, Marignier, Romain, Tedder, Thomas, van Pelt, Danielle, Broadley, Simon, Chitnis, Tanuja, Wingerchuk, Dean, Pandit, Lekha, Leite, Maria Isabel, Apiwattanakul, Metha, Kleiter, Ingo, Prayoonwiwat, Naraporn, Han, May, Hellwig, Kerstin, van Herle, Katja, John, Gareth, Hooper, D Craig, Nakashima, Ichiro, Sato, Douglas, Yeaman, Michael R, Waubant, Emmanuelle, Zamvil, Scott, Stüve, Olaf, Aktas, Orhan, Smith, Terry J, Jacob, Anu, and O'Connor, Kevin

Subjects
Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Humans, Neuromyelitis Optica, Magnetic Resonance Imaging, Clinical Trials as Topic, Diffusion Tensor Imaging, Neurosciences, Clinical Research, Brain Disorders, Biomedical Imaging, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Neurological, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

Brain parenchymal lesions are frequently observed on conventional magnetic resonance imaging (MRI) scans of patients with neuromyelitis optica (NMO) spectrum disorder, but the specific morphological and temporal patterns distinguishing them unequivocally from lesions caused by other disorders have not been identified. This literature review summarizes the literature on advanced quantitative imaging measures reported for patients with NMO spectrum disorder, including proton MR spectroscopy, diffusion tensor imaging, magnetization transfer imaging, quantitative MR volumetry, and ultrahigh-field strength MRI. It was undertaken to consider the advanced MRI techniques used for patients with NMO by different specialists in the field. Although quantitative measures such as proton MR spectroscopy or magnetization transfer imaging have not reproducibly revealed diffuse brain injury, preliminary data from diffusion-weighted imaging and brain tissue volumetry indicate greater white matter than gray matter degradation. These findings could be confirmed by ultrahigh-field MRI. The use of nonconventional MRI techniques may further our understanding of the pathogenic processes in NMO spectrum disorders and may help us identify the distinct radiographic features corresponding to specific phenotypic manifestations of this disease.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results